|
|
 |
|
Viewing report
|
|
|
|
Shionogi & Co., Ltd: PharmaVitae Profile
Datamonitor, March 2011, Pages: 82
This analysis examines the historical and forecast performance for Shionogi in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Shionogi's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source.
Highlights
- Strategic insight into the prospects for Shionogi over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark Shionogi's performance against key rivals in the prescription pharmaceutical sector
- Discover how Shionogi has utilized M&A to become one of the world's largest multi-disciplinary healthcare companies
- Investigate the strategies being employed by Shionogi to overcome the challenging dynamics of the Japanese market and restructuring in the US
Customers who bought this item also bought
Shionogi: Performance, Products, Pipeline and Potential
Schering-Plough Corporation: PharmaVitae Profile
ASTRAZENECA, SHIONOGI - Top Line Results from SATURN confirms Lipitor Generic Entry Is Detrimental for Crestor
AstraZeneca plc: PharmaVitae Profile
Mitsubishi Tanabe Pharma Corporation: PharmaVitae Profile
Shionogi & Co., Ltd. - Strategy, SWOT, and Corporate Finance Report
Takeda Pharmaceutical Co. Ltd: PharmaVitae Profile
Bayer Schering Pharma AG: PharmaVitae Profile
H. Lundbeck A/S: PharmaVitae Profile
Shionogi & Co., Ltd. (4507) - Financial and Strategic SWOT Analysis Review
|
|
|
|
